Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy
- Cite this article as:
- McGowan, T.A., Zhu, Y. & Sharma, K. Curr Diab Rep (2004) 4: 447. doi:10.1007/s11892-004-0055-z
Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming growth factor-â (TGF-â) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-â on matrix accumulation but have also found that blocking TGF-â may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-â in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.